$EPRX News

Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25

HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11

Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate

Eupraxia Pharmaceuticals shares are trading lower after the company announced it priced its $55 million public offering of 6.4 million shares and pre-funded warrants at $7.00 per share.

Eupraxia Pharmaceuticals shares are trading lower after the company announced it priced its $55 million public offering of 6.4 million shares and pre-funded warrants at $7.00 per share.

Eupraxia Pharmaceuticals Prices $55M Public Offering Of 6.4M Common Shares And Pre-Funded Warrants At $7.00 Per Share To Advance EP-104GI Trials

Eupraxia Pharmaceuticals shares are trading lower after the company announced a proposed public offering.

Eupraxia Pharmaceuticals Commences Common Stock Offering; Terms Not Disclosed

Cantor Fitzgerald Maintains Overweight on Eupraxia Pharmaceuticals, Raises Price Target to $19

HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target

Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Eupraxia Pharmaceuticals shares are trading higher after the company reported tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial in eosinophilic esophagitis showing near-complete improvement on biopsy.

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy

Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis

Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why

Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26%

Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet